Nyxoah (NYXH)
NASDAQ:NYXH
Want to see NYXH full AI Analyst Report?
Earnings Data
Report Date
Aug 05, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.48Last Year’s EPS
-0.64Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed solid commercial progress and encouraging leading indicators: sequential worldwide revenue growth (+13%), strong U.S. momentum (+25% U.S. sequential), expanding surgeon/account footprint, a large prior-authorization funnel, and reimbursement clarity (CMS C-codes and 100% prior-authorization approvals reported). Management provided growth guidance and a clear product roadmap (Genio 2.2) expected to materially improve gross margins in 2027. Offsetting risks are near-term gross margin pressure from resolved production yield issues (Q1 margin 57% vs 62% prior), increased operating expenses to support the U.S. launch, and cash/runway considerations given modest cash on hand and substantial FY OpEx guidance. On balance the progress on commercialization, reimbursement de-risking, and product roadmap outweigh the near-term margin and cash challenges.Company Guidance
Sequential Worldwide Revenue Growth
Net revenue of ~€6.4M in Q1 2026 (€6.7M gross before €0.3M deferrals), representing 13% sequential growth vs Q4 2025.
Strong U.S. Commercial Momentum
U.S. net revenue of €4.3M in Q1 2026, ~25% sequential growth vs prior quarter; management delivered on commitment to ~25% sequential U.S. growth and expects Q2 U.S. growth of ~25%–30% sequentially with further acceleration in H2.
Commercial Launch KPIs and Field Expansion
Q1 additions included 62 new surgeons trained (total 207 trained), 34 new accounts activated (total 91 active of >125 targeted), 15 new sales reps (total 40 fully operational), and capacity to cover ~200 high-volume U.S. accounts entering Q2.
Robust Prior-Authorization Funnel
241 new patients submitted under prior authorization and pending at quarter end (versus ~100 at end-Q4), with reported 100% approval rate on reviewed commercial prior authorizations.
Reimbursement Clarity and 100% Approval in WISER
CMS issued AGNS-specific facility C-codes (facility fee parity vs existing codes); physician CPT payment remained at ~$732. WISER pilot (AI-supported prior authorization) delivered 100% approval rate for submitted Medicare patients. Management characterized reimbursement as de-risked for 2026–2027.
International Performance and Market Entries
International revenue was flat vs prior year quarter but overcame typical seasonality vs Q4 2025 driven by deeper penetration in Germany, continued Middle East adoption, and successful UK and Netherlands entries.
Clear Product Roadmap to Improve Margins
Planned Genio 2.2 upgrade (new sleep wearable, upgraded software, low-cost disposable patch + activation chip) targeted for early 2027 to materially improve patient experience and gross margin (step to low-70s expected in 2027, long-term >80%).
Full-Year Guidance
Company guides worldwide net revenue €36M–€40M for FY2026, gross margin 60%–62%, total operating expenses €97M–€99M, and non-GAAP cash operating expenses €88M–€90M; expects U.S. sequential growth and back-half acceleration (Q3/Q4 growth rates guided to rise into 40%–50% range sequentially).
Cash and Financing Visibility
Cash and cash equivalents plus financial assets of €25.9M at March 31, 2026, and expected draw of ~€13.8M from second tranche of EIB loan in 2026 to support runway.
Market Research Supporting Adoption
Survey of >100 U.S. HGNS implanters: 88% of ENTs value multiple AGNS options; all Genio-trained surgeons plan to adopt Genio. Top reasons cited: bilateral stimulation, no implanted battery, and alternative therapy option; 84% collaborate with sleep medicine.
NYXH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NYXH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2026 | $3.07 | $3.08 | +0.33% |
Mar 19, 2026 | $3.09 | $3.08 | -0.32% |
Nov 13, 2025 | $5.31 | $5.00 | -5.84% |
Aug 18, 2025 | $6.57 | $6.27 | -4.57% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Nyxoah (NYXH) report earnings?
Nyxoah (NYXH) is schdueled to report earning on Aug 05, 2026, After Close (Confirmed).
What is Nyxoah (NYXH) earnings time?
Nyxoah (NYXH) earnings time is at Aug 05, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NYXH EPS forecast?
NYXH EPS forecast for the fiscal quarter 2026 (Q2) is -0.48.